AcousticaBio is a technology company.
AcousticaBio is a technology company.
AcousticaBio has raised $50K across 1 funding round.
AcousticaBio has raised $50K in total across 1 funding round.
AcousticaBio is a venture-backed, NIH-funded biotechnology company specializing in advanced fluid processing technology to improve the delivery of novel therapeutics, particularly biologics. Their proprietary acoustophoretic technology enables the creation of ultra-high concentration antibody formulations that facilitate painless, subcutaneous injections as an alternative to traditional intravenous (IV) treatments. This innovation targets patients, pharmaceutical companies, and healthcare providers by improving drug stability, reducing immune responses, lowering costs, and enabling self-administration, thereby addressing significant challenges in drug delivery and patient experience[1][2].
Founded in 2021-2022 as a spinout from Harvard, AcousticaBio was established by Daniele Foresti, a PhD mechanical engineer from ETH Zürich and inventor of the core technology. The company quickly gained traction through strong preclinical safety and efficacy data and collaborations with leading global biopharmaceutical firms. Its founding team includes experienced biotech entrepreneurs and industry veterans, such as Jonathan Thon and Anjali Kumar, who bring deep expertise in biopharmaceutical development and commercialization. The idea emerged from the need to overcome limitations in biologic drug formulation and delivery, leveraging sound-based microfluidic technology to precisely control microdroplet formation for improved therapeutic outcomes[1][3].
AcousticaBio rides the growing trend toward patient-centric, decentralized drug delivery, which is increasingly important due to rising biologic drug use and healthcare cost pressures. The shift from hospital-based IV infusions to at-home subcutaneous injections aligns with broader healthcare system goals of improving accessibility, reducing costs, and enhancing patient quality of life. Advances in microfluidics and acoustophoretic technologies position AcousticaBio at the forefront of next-generation biomanufacturing and drug formulation innovation. Their technology addresses critical market needs for stable, high-concentration biologics that are easier to administer, supporting the expansion of biologics into new therapeutic areas and patient populations[2][4].
Looking ahead, AcousticaBio is poised to expand its collaborations with pharmaceutical companies and advance its technology toward clinical and commercial stages. Trends such as personalized medicine, increased biologic drug approvals, and demand for home-based therapies will likely accelerate adoption of their platform. Continued innovation in acoustophoretic processing and formulation science could broaden their impact across multiple therapeutic modalities. As healthcare systems globally seek more efficient and patient-friendly drug delivery solutions, AcousticaBio’s technology may become a key enabler of this transformation, reinforcing its role as a pioneering force in life sciences manufacturing and therapeutic delivery[1][2].
AcousticaBio has raised $50K in total across 1 funding round.
AcousticaBio has raised $50K across 1 funding round. Most recently, it raised $50K Seed in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $50K Seed |